Continuous biomarker wearables are moving beyond glucose—but the technology is still early
ARPA-H is funding modular wearable biosensors for hormones, inflammation, medication levels, and more. The program is a major R&D signal, not evidence that consumer devices are ready.
Continuous biomarker wearables beyond glucose are a serious research direction, but they are not yet a proven consumer category. ARPA-H's Delphi program is funding modular sensors aimed at hormones, inflammatory markers, medication levels, and other biological signals. The announcement establishes investment and development milestones—not clinical accuracy, usefulness, regulatory clearance, or readiness for self-interpretation.
The short answer
ARPA-H is backing a major effort to build wearable biosensors that go beyond heart rate and glucose. The Delphi program is a strong signal that continuous biomarker sensing could become much broader, but the funded devices are still research-and-development projects. Treat the announcement as a technology roadmap, not a product recommendation.
What ARPA-H is funding
The agency announced up to $117.4 million over 4.5 years for teams developing interoperable wearable biosensors. The goal is to replace bulky, expensive, single-purpose sensors with modular components that can be combined for different biological targets and medical applications.
What the wearables may measure
The program describes potential measurement targets including hormones, inflammatory markers, and medication levels. Performer projects include applications related to heart failure, inflammation, perimenopause, and post-heart-attack monitoring. Those are intended development targets, not validated consumer features.
Why modular chiplets matter
Delphi is built around small modular microelectronic components, or chiplets, for sensing, processing, power, communications, and security. If the approach works, developers could reuse a common platform while swapping the biological recognition component for different targets. That could make future sensor development faster and cheaper than building a completely new device for every biomarker.
The milestones are the real story
ARPA-H's milestones include interoperability demonstrations, in-vivo prototypes, and eventual clinical-trial or human-factors work. Those checkpoints matter more than the announcement itself because they will show whether the sensors can move from engineering concepts toward reliable human use.
What has not been proven
The program has not yet established analytical accuracy, clinical validity, consumer usefulness, regulatory clearance, privacy performance, affordability, or whether people can safely interpret the resulting data without professional context. A wearable that can detect a molecule is not automatically a useful health decision tool.
Why BOTH is watching this
Wearables are moving from activity and sleep estimates toward richer biological sensing. That could eventually change what a consumer health platform, Test Lab, or biomarker dashboard can do. BOTH will track the Delphi milestones and separate laboratory performance, regulatory status, clinical evidence, and real-world usefulness as those data appear.
Research-and-development explainer prepared with AI assistance and checked against the official ARPA-H Delphi program announcement. The devices are under development; no clinical efficacy, consumer utility, regulatory clearance, or BOTH testing is claimed.
Sources
Go deeper
Evidence
Do something
know what matters next.
one useful update at a time. no wellness noise.